Search ↗

Comparison

Cerebrolysin vs Dihexa

Both are nootropic & neuro, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Cerebrolysin is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

Cerebrolysin Dihexa
Class Nootropic & neuro Nootropic & neuro
Evidence Clinical trials Animal models only
Human trials ~40 None published
Half-life Not established (mixture) ~10-12 hours
Reported range 5-30 g 8-45 mg
Frequency Daily intravenous infusion or intramuscular injection over 10-20 day courses Once daily
Routes Intravenous, Intramuscular Oral, Subcutaneous, Topical
FDA approved No No
Research use only Yes Yes
Banned in sport No No
Studied for Vascular dementia, Stroke recovery, Traumatic brain injury, Alzheimer's research Cognitive research, Neurodegeneration research
Reported side effects Injection-site reactions, Dizziness, Sweating, Agitation Headache, Overstimulation, Poorly characterised

Cerebrolysin

Cerebrolysin is not a single molecule but a standardised enzymatic hydrolysate of purified porcine brain protein, containing low-molecular-weight peptides and free amino acids. It is proposed to act in a neurotrophic-like manner, supporting neuronal survival, synaptic plasticity and neurogenesis in a way that partly mimics endogenous neurotrophic factors. Clinical evidence in vascular dementia and traumatic brain injury exists and is moderately encouraging, though heterogeneity across trials is substantial.

Dihexa

Dihexa is a small peptidomimetic derived from angiotensin IV, engineered for blood-brain barrier penetration. It is understood to potentiate hepatocyte growth factor signalling at the c-Met receptor, driving synaptogenesis and dendritic spine formation. The often-quoted figure describing it as seven orders of magnitude more potent than BDNF comes from an in vitro assay in a rodent model, not from human data, and no human trial has been published.

Cerebrolysin vs Dihexa: common questions

What is the difference between Cerebrolysin and Dihexa?

Both are nootropic & neuro. Cerebrolysin: A porcine brain-derived peptide preparation used clinically across Europe and Asia for dementia and stroke. Dihexa: An angiotensin IV derivative reported in animal work to be dramatically more potent than BDNF at promoting synaptogenesis.

Which has stronger evidence, Cerebrolysin or Dihexa?

Cerebrolysin has the stronger evidence base (clinical trials, about 40 human studies) compared with Dihexa (animal models only).

Are Cerebrolysin and Dihexa FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  2. PubChem compound record (CID 129010512) ↗ · structure, identifiers, synonyms

Published literature

  1. Cook AM, Michas M, Robbins B. Update on Neuroprotection after Traumatic Brain Injury.CNS Drugs 2025.PubMed 40087248 · doi:10.1007/s40263-025-01173-9
  2. Cui S, Chen N, Yang M, et al.. Cerebrolysin for vascular dementia.Cochrane Database Syst Rev 2019.PubMed 31710397 · doi:10.1002/14651858.CD008900.pub3
  3. Ziganshina LE, Abakumova T, Hoyle CH. Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2020.PubMed 32662068 · doi:10.1002/14651858.CD007026.pub6
  4. Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2017.PubMed 28430363 · doi:10.1002/14651858.CD007026.pub5
  5. Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2016.PubMed 27918088 · doi:10.1002/14651858.CD007026.pub4
  6. Ziganshina LE, Abakumova T. Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2015.PubMed 26083192 · doi:10.1002/14651858.CD007026.pub3
  7. Masserini F, Gendarini C, Baso G, et al.. Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis.Alzheimers Dement 2025.PubMed 41198594 · doi:10.1002/alz.70840
  8. Bogolepova AN. [Cognitive impairment in post-traumatic stress disorder].Zh Nevrol Psikhiatr Im S S Korsakova 2024.PubMed 38884432 · doi:10.17116/jnevro202412405169
  9. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  10. Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease.J Alzheimers Dis 2015.PubMed 25649658 · doi:10.3233/JAD-142814
  11. Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies.Neurosci Biobehav Rev 2018.PubMed 29733881 · doi:10.1016/j.neubiorev.2018.05.005
  12. Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.Prog Neurobiol 2015.PubMed 25455861 · doi:10.1016/j.pneurobio.2014.11.004

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.